Research Research Programs Biotechnology, Imaging & Drug Development Systems, Pathways & Targets Cancer Control Clinical Research Stern Center for Cancer Clinical Trials and Research Disease-Oriented Teams Protocol Review and Monitoring Committee Research Resources Membership Guidelines Shared Resources Acknowledgement of Grant and Shared Resources Anti-Cancer Challenge Research Anti-Cancer Challenge Pilot Awards Anti-Cancer Challenge Past Awardees Team Funds Centers & Institutes Space Management and Requests Funding Opportunities A1 Bridge Funding Cancer Health Disparity Research and Interventional Studies Systems, Pathways & Targets Home Research Research Programs Systems, Pathways & Targets The Systems, Pathways & Targets (SPT) program integrates traditional cancer biology experimentalists with members who have expertise in the systems biology of cancer to study the fundamental biology of individual cancer cells as well as the interactions among cells in the tumor environment and metastatic sites. SPT Program Leadership John Lowengrub, PhD Program Co-Leader, Systems, Pathways & Targets Professor, Mathematics Angela Fleischman, MD, PhD Program Co-Leader, Systems, Pathways & Targets Associate Professor, Division of Hematology/Oncology Roberto Tinoco, PhD Assistant Program Leader, Systems, Pathways & Targets Assistant Professor, Molecular Biology & Biochemistry Program Overview The overall goal of the Systems, Pathways & Targets (SPT) Program is to discover new aspects of cancer biology that can be exploited for the development of novel treatments and diagnostics. Led by Program Co-Leaders (PLs) John Lowengrub, PhD and Angela Fleischman, MD, PhD, SPT members include cell biologists, immunologists, geneticists, systems biologists, computational scientists, and clinical investigators. The Program leverages these diverse perspectives to build collaborative teams that tackle long-standing problems using bold and innovative approaches. Working at different scales, from molecules and cells to tissues and organs, SPT members study the fundamental biology of individual cancer cells as well as the interactions among cells in the tumor environment and metastatic sites to identify targets for intervention. Several SPT members are physician-scientists with independent research programs and are well-positioned to translate discoveries from bench to bedside as novel therapies and important new diagnostics. Importantly, SPT leadership actively connects basic scientists with clinicians through the CFCCC’s Disease-Oriented Teams (DOTs) and via the annual Cancer Center retreat. These interactions have facilitated access to tumor tissue samples for laboratory research projects and led to new clinical trials